HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Heart Disease and Diabetes

 

The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.

Top New Trial Data at ESC Congress 2022

September 03, 2022

Although the European Society of Cardiology (ESC) Congress 2022 may be over, our editorial team is recapping the most popular new trial data from the ESC’s first in-person conference since 2019. The top 5 trials, which were chosen based on total views per article, includes DELIVER, TIME, AXIOMATIC-SSP, FIDELITY, and DANCAVAS.

In Patients with Cancer and Diabetes, SGLT2 Inhibitors Could Provide Cardioprotection Against Anthracyclines

August 24, 2022

An analysis of patients treated in the Massachusetts General Brigham hospital system provides into the potential cardioprotective benefits of SGLT2 inhibitor use among patients with diabetes and cancer receiving treatment with anthracyclines.

Study Warns of Significant Increases in Diabetes and Cardiovascular Disease by 2060

August 01, 2022

Using data from the 2020 US Census report and recent NHANES survey data, investigators from Massachusetts General Hospital detail expected increases in the prevalence of cardiovascular risk factors and cardiovascular disease among the US population by 2060.

Medicare Advantage Beneficiaries Less Likely to Receive GLP-1 RA and SGLT2 Inhibitor Prescriptions

July 14, 2022

A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.

Metformin, Lifestyle Changes Not Enough to Stave off CVD Risk in T2D

May 27, 2022

Data from an analysis of follow-up data from the landmark DPPOS study provide insight into the apparent lack of cardiovascular risk reduction provided to patients with prediabetes from metformin and lifestyle interventions.